The diversion of blood flow through arterialization of the deep veins in the foot holds up well at 2 years as a therapy for ...

At 2 years, the limb salvage rate was 65%, with “still very good wound healing out to 2 years in this group of patients, and ...

The trial was small and halted early, but investigators say the inflammatory hypothesis in TAVI is worth pursuing further.

Male gender expression, a metric capturing societal pressures for men to be masculine, could be leveraged to improve health.

The data thus far suggest fewer repeat interventions with the newly FDA approved resorbable device compared with PTA.

No matter whether patients had CAD or not, the simpler regimen was linked to less mortality and major bleeding at 6 months.

WASHINGTON, DC—How patients weigh the opinions of their family and friends when making decisions about PAD varies by sex and ...

WASHINGTON, DC—For vascular closure after transfemoral TAVI, a strategy that combines suture- and plug-based devices halves ...

The trial adds much-needed randomized data to an area where it’s been lacking. Questions about methods muddy interpretation.

Fewer rehospitalizations and better functional and QoL outcomes point to TAVI as a good choice, but longer-term data are ...

The data hint at sirolimus becoming a useful option or even a replacement for paclitaxel, but full 5-year follow-up is needed ...

With further refinement and defined thresholds for treatment, this technology has the potential to guide treatment decisions.